Pivot Bio Joins AIM for Climate as Innovation Sprint Partner
Pivot Bio, agriculture’s leading nitrogen innovator, joins the Agriculture Innovation Mission for Climate (AIM for Climate) as an Innovation Sprint Partner, committing at least $291 million in product development funding over four years to accelerate the adoption of climate-resilient microbial nitrogen fertilizers.
Pivot Bio introduced the world’s first nitrogen-producing microbes to U.S. farmers in 2018. Since that time, the company has introduced multiple microbial nitrogen products for wheat, sorghum and other small grains in addition to its flagship product for corn. Farmers have quickly converted their nitrogen management programs to include nitrogen produced by Pivot Bio’s microbes, while reducing their dependence on synthetic nitrogen fertilizer.
“Microbial nitrogen fertilizer has the potential to permanently and immediately deliver reductions in GHG emissions, while delivering co-benefits to watershed health, biodiversity, and farmer margins,” said Karsten Temme, Ph.D., co-founder and CEO of Pivot Bio. “This could be one of the most important technologies for accelerating progress against the world’s 2030 Sustainable Development Goals.”
Adhering to the root of the plants, Pivot Bio’s microbes convert atmospheric nitrogen to a usable source of the critical nutrient throughout a crop’s growing season. These microbes stay with the plant, eliminating the waste associated with fossil fuel-dependent synthetic fertilizers that are applied on top of the ground. Unlike synthetic fertilizers, Pivot Bio’s microbial fertilizer does not leach into waterways nor volatilize into the air, improving air and water quality.
“Farmers are the foundation of the world’s food system and humanity's greatest stewards of our land,” said Temme. “Pivot Bio is committed to partnering with them to deliver better nitrogen while helping to heal the planet.”
Over the next four years, Pivot Bio will continuously improve the nitrogen production capacity of the Company’s microbes and expand into new geographic markets to help more of the world’s farmers nourish their crops with the most climate-friendly and easy-to-use nitrogen on the market.
“As an AIM for Climate Innovation Sprint Partner, we will bring together the best minds and ideas to accelerate our pace of product development and increase farmer access to a dependable and sustainable nitrogen,” said Temme. “We are working toward a world where microbial nitrogen is the main source of crop nutrition and encourage farmers, government leaders and members of the private sector to get in touch to join us in that mission.”
COP27, the United Nations Climate Change Conference, has been called the “food COP,” devoting an entire day, November 12, to agriculture for the first time. Conservative estimates place the total emissions associated with synthetic nitrogen fertilizer at approximately 9 units of CO2eq for every unit of synthetic nitrogen fertilizer produced. Approximately one-third of those emissions are caused by the Haber-Bosch manufacturing process, with direct and indirect emissions of nitrous oxide (N2O) accounting for the rest. Replacing synthetic nitrogen fertilizer with nitrogen-producing microbes avoids these emissions and has the potential to reduce water use (more than 15,000 liters per ton of synthetic N fertilizer) and improve human health outcomes by reducing ozone depletion and particulate generation.
To learn more about Pivot Bio’s innovation sprint, please watch this video message.
About Pivot Bio:
At Pivot Bio, we believe in meeting the needs of the present without compromising the needs of future generations. Our unparalleled understanding of the crop microbiome will help create a future with cleaner water and air. We are dedicated to providing farmers with solutions so they can grow high-quality, environmentally-responsible, and sustainably-focused crops that help feed families worldwide. For more information, visit www.pivotbio.com and follow us on LinkedIn, Twitter, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221111005122/en/
Contact information
Mitchell Craft
405-473-4553
media@pivotbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom